SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 16, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2020 after the close of market on Thursday, July 30, 2020 . Company management will host a conference call and webcast
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 11, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of an independent study showing that the Envisia Genomic Classifier enables physicians to more confidently diagnose idiopathic pulmonary fibrosis (IPF), a progressive lung
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 9, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced its submission of a De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter ® Dx LymphMark ™ Assay, a novel, genomic lymphoma subtyping test.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present virtually at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10 , at 12:40
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 21, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 3:30 p.m. Eastern Time .
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 3:00 p.m. Eastern Time .
Total Testing and Product Revenue Increased 20% to $30.4 Million Genomic Testing Volume Grew 15% to 10,559 Executed Exclusive Licensing Agreement with Yale University To Advance Novel, Blood-Based Genomic IPF Monitoring Test on nCounter Platform Company Outlines COVID-19 Impact and Response
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced that the company has launched “More About You,” a web-based campaign that is designed to educate patients about thyroid nodules, and empower them to both engage in conversations with their
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Veracyte, Inc. (Nasdaq: VCYT) and Yale University today announced an exclusive licensing agreement to advance the first genomic test for
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
